|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplemental eTable 1. Propensity Score Model Results of Probability of Using Statin.** | | | | | |
|  |  |  | **95% CI** | | |
| **Parameter** | **Estimate** | **Odds Ratios** | **Lower** | **Upper** | **P value** |
| **Age, per year** | -0.0091 | 0.991 | 0.989 | 0.993 | <.0001 |
| **Male** | -0.2906 | 0.748 | 0.715 | 0.782 | <.0001 |
| **Year of Index Date** |  |  |  |  |  |
| **2000** |  | 1 |  |  |  |
| **2001** | 0.236 | 1.266 | 0.941 | 1.703 | 0.1187 |
| **2002** | 0.5376 | 1.712 | 1.297 | 2.259 | 0.0001 |
| **2003** | 1.1655 | 3.207 | 2.462 | 4.179 | <.0001 |
| **2004** | 1.3842 | 3.992 | 3.077 | 5.178 | <.0001 |
| **2005** | 1.4876 | 4.426 | 3.416 | 5.736 | <.0001 |
| **2006** | 1.5418 | 4.673 | 3.607 | 6.054 | <.0001 |
| **2007** | 1.6587 | 5.253 | 4.057 | 6.801 | <.0001 |
| **2008** | 1.7142 | 5.552 | 4.289 | 7.189 | <.0001 |
| **2009** | 1.8589 | 6.417 | 4.959 | 8.303 | <.0001 |
| **2010** | 2.1151 | 8.29 | 6.406 | 10.728 | <.0001 |
| **2011** | 2.2177 | 9.186 | 6.955 | 12.133 | <.0001 |
| **Month of Index Date** |  |  |  |  |  |
| **January** |  | 1 |  |  |  |
| **February** | 0.0107 | 1.011 | 0.913 | 1.119 | 0.8368 |
| **March** | 0.0887 | 1.093 | 0.99 | 1.206 | 0.0791 |
| **April** | 0.1152 | 1.122 | 1.01 | 1.246 | 0.0314 |
| **May** | 0.0657 | 1.068 | 0.96 | 1.187 | 0.2245 |
| **June** | 0.0388 | 1.04 | 0.937 | 1.153 | 0.4623 |
| **July** | 0.1003 | 1.106 | 0.998 | 1.225 | 0.0548 |
| **August** | 0.0992 | 1.104 | 0.996 | 1.224 | 0.0585 |
| **September** | 0.0882 | 1.092 | 0.984 | 1.212 | 0.0971 |
| **October** | 0.028 | 1.028 | 0.928 | 1.14 | 0.5951 |
| **November** | 0.1004 | 1.106 | 0.997 | 1.226 | 0.0572 |
| **December** | 0.1188 | 1.126 | 1.016 | 1.248 | 0.0231 |
| **Monthly income, NT dollars** |  |  |  |  |  |
| **Dependent** |  | 1 |  |  |  |
| **<19,100** | -0.1884 | 0.828 | 0.778 | 0.882 | <.0001 |
| **19,100**−**41,999** | -0.1277 | 0.88 | 0.837 | 0.926 | <.0001 |
| **≥42,000** | 0.1016 | 1.107 | 1 | 1.225 | 0.0495 |
| **Urbanizationa** |  |  |  |  |  |
| **Level 1** |  | 1 |  |  |  |
| **Level 2** | -0.0972 | 0.907 | 0.867 | 0.949 | <.0001 |
| **Level 3** | -0.0641 | 0.938 | 0.85 | 1.035 | 0.2013 |
| **Level 4 (rural area)** | -0.0024 | 0.998 | 0.794 | 1.254 | 0.9836 |
| **Outpatient Visits of Cardiology, in the past one year** |  |  |  |  |  |
| **0 visits** |  | 1 |  |  |  |
| **1**−**5 visits** | 0.1974 | 1.218 | 1.151 | 1.289 | <.0001 |
| **6**−**10 visits** | 0.4847 | 1.624 | 1.493 | 1.765 | <.0001 |
| **>10 visits** | 0.3726 | 1.451 | 1.308 | 1.611 | <.0001 |
| **Outpatient Visits of Metabolism &Endocrinology, in the past one year** |  |  |  |  |  |
| **0 visits** |  | 1 |  |  |  |
| **1**−**5 visits** | 0.2112 | 1.235 | 1.149 | 1.327 | <.0001 |
| **6**−**10 visits** | 0.4429 | 1.557 | 1.385 | 1.75 | <.0001 |
| **>10 visits** | 0.5344 | 1.706 | 1.461 | 1.993 | <.0001 |
| **Charlson Comorbidity Index Scoreb** | -0.0411 | 0.96 | 0.944 | 0.976 | <.0001 |
| **Duration of diagnosis of diabetes, month** | -0.00158 | 0.998 | 0.998 | 0.999 | <.0001 |
| **Adapted Diabetes Complications Severity Index scorec** | 0.0112 | 1.011 | 0.995 | 1.027 | 0.1629 |
| **Hospitalization for peripheral arterial disease** | -0.591 | 0.554 | 0.476 | 0.645 | <.0001 |
| **Drugs for diabetes** |  |  |  |  |  |
| **Acarbose inhibits enzymes** | 0.2433 | 1.275 | 1.165 | 1.397 | <.0001 |
| **Sulfonylurea** | 0.2626 | 1.3 | 1.238 | 1.366 | <.0001 |
| **Insulin** | 0.1397 | 1.15 | 1 | 1.322 | 0.0501 |
| **Metformin** | 0.2755 | 1.317 | 1.255 | 1.383 | <.0001 |
| **Thiazolidinediones** | 0.4949 | 1.64 | 1.501 | 1.793 | <.0001 |
| **Glinide** | 0.1916 | 1.211 | 1.085 | 1.352 | 0.0006 |
| **Dipeptidyl peptidase-4 inhibitor** | 0.273 | 1.314 | 1.069 | 1.614 | 0.0094 |
| **Anti-hypertensive drug** |  |  |  |  |  |
| **ACE inhibitor or ARB** | 0.2933 | 1.341 | 1.274 | 1.411 | <.0001 |
| **Alpha-blocker** | -0.0636 | 0.938 | 0.833 | 1.057 | 0.2934 |
| **Beta-blocker** | 0.0528 | 1.054 | 0.995 | 1.117 | 0.0724 |
| **Calcium channel blocker** | -0.00793 | 0.992 | 0.943 | 1.043 | 0.7571 |
| **Diuretics** | 0.0585 | 1.06 | 0.996 | 1.129 | 0.0673 |
| **Other anti-hypertensive drug** | -0.1702 | 0.844 | 0.717 | 0.993 | 0.0409 |
| **Other concomitant medications** |  |  |  |  |  |
| **Antiplatelet** d | 0.4173 | 1.518 | 1.443 | 1.597 | <.0001 |
| **Steroid** | -0.0377 | 0.963 | 0.886 | 1.046 | 0.3734 |
| **Nitrate** | 0.1182 | 1.125 | 1.023 | 1.239 | 0.0156 |
| **NSAID** | 0.0809 | 1.084 | 1.032 | 1.14 | 0.0015 |
| **PPI** | -0.0967 | 0.908 | 0.794 | 1.038 | 0.156 |
| **SSRI** | 0.1281 | 1.137 | 0.977 | 1.323 | 0.098 |
| **Comorbidities** |  |  |  |  |  |
| **Coronary artery disease** | 0.1255 | 1.134 | 1.077 | 1.193 | <.0001 |
| **Cerebrovascular disease** | 0.0718 | 1.074 | 1.014 | 1.138 | 0.0144 |
| **Hypertension** | 0.2085 | 1.232 | 1.16 | 1.308 | <.0001 |
| **Heart failure** | -0.1685 | 0.845 | 0.784 | 0.91 | <.0001 |
| **Peptic ulcer disease** | 0.00953 | 1.01 | 0.961 | 1.061 | 0.7068 |
| **Liver disease** | 0.0372 | 1.038 | 0.99 | 1.089 | 0.1268 |
| **Chronic kidney disease** | 0.0637 | 1.066 | 0.996 | 1.141 | 0.0666 |
| **Atrial fibrillation** | -0.4198 | 0.657 | 0.579 | 0.746 | <.0001 |
| **Valvular heart disease** | -0.0741 | 0.929 | 0.864 | 0.998 | 0.0453 |
| **Cancer** | -0.0854 | 0.918 | 0.845 | 0.997 | 0.0424 |
| **Physically limiting conditions** | -0.0339 | 0.967 | 0.905 | 1.033 | 0.3178 |
| **Autoimmune disease** | 0.00114 | 1.001 | 0.908 | 1.104 | 0.9817 |
| a Urbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.  b Charlson Comorbidity Index score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the cumulative mortality[.](#_ENREF_9)  cAdapted Diabetes Complications Severity Index is a 13-point scale from 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic, ranging from each complication. Each complication produced a numeric score ranging from 0 to 2 (0 = no abnormality, 1 = some abnormality, 2 = severe abnormality)  d Including aspirin, clopidogrel, ticlopidine and cilostazol.  *Abbreviations:* NT dollars, new Taiwan dollars; NSAID, Non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, Selective serotonin re-uptake inhibitors. | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplemental eTable 2. Propensity Score Model Results of Probability of Using Non-Statin Lipid Lowering Agent.** | | | | | |
|  |  |  | **95% CI** | | |
| **Parameter** | **Estimate** | **Odds Ratios** | **Lower** | **Upper** | **P value** |
| **Age, per year** | -0.0304 | 0.97 | 0.967 | 0.973 | <.0001 |
| **Male** | 0.1396 | 1.15 | 1.077 | 1.228 | <.0001 |
| **Year of Index Date** |  |  |  |  |  |
| **2000** |  | 1 |  |  |  |
| **2001** | -0.1592 | 0.853 | 0.665 | 1.094 | 0.211 |
| **2002** | -0.0981 | 0.907 | 0.716 | 1.148 | 0.4152 |
| **2003** | 0.1472 | 1.159 | 0.923 | 1.454 | 0.2036 |
| **2004** | 0.1765 | 1.193 | 0.955 | 1.49 | 0.1196 |
| **2005** | 0.1412 | 1.152 | 0.922 | 1.439 | 0.2136 |
| **2006** | 0.2165 | 1.242 | 0.995 | 1.55 | 0.0559 |
| **2007** | 0.2681 | 1.307 | 1.048 | 1.631 | 0.0176 |
| **2008** | 0.1861 | 1.205 | 0.963 | 1.506 | 0.1025 |
| **2009** | 0.2327 | 1.262 | 1.01 | 1.576 | 0.0403 |
| **2010** | 0.3171 | 1.373 | 1.097 | 1.718 | 0.0056 |
| **2011** | 0.3739 | 1.453 | 1.09 | 1.938 | 0.0108 |
| **Month of Index Date** |  |  |  |  |  |
| **January** |  | 1 |  |  |  |
| **February** | -0.0422 | 0.959 | 0.819 | 1.123 | 0.6008 |
| **March** | 0.0261 | 1.026 | 0.881 | 1.196 | 0.7388 |
| **April** | -0.0525 | 0.949 | 0.806 | 1.117 | 0.5292 |
| **May** | 0.0713 | 1.074 | 0.916 | 1.259 | 0.3784 |
| **June** | 0.0139 | 1.014 | 0.867 | 1.185 | 0.8619 |
| **July** | 0.1067 | 1.113 | 0.955 | 1.296 | 0.1703 |
| **August** | 0.1462 | 1.157 | 0.994 | 1.348 | 0.0597 |
| **September** | 0.1472 | 1.159 | 0.994 | 1.35 | 0.0594 |
| **October** | 0.1072 | 1.113 | 0.957 | 1.294 | 0.1635 |
| **November** | 0.0725 | 1.075 | 0.922 | 1.255 | 0.3567 |
| **December** | 0.13 | 1.139 | 0.979 | 1.325 | 0.0922 |
| **Monthly income, NT dollars** |  |  |  |  |  |
| **Dependent** |  | 1 |  |  |  |
| **<19,100** | -0.03 | 0.97 | 0.882 | 1.068 | 0.5413 |
| **19,100**−**41,999** | 0.052 | 1.053 | 0.974 | 1.139 | 0.1907 |
| **≥42,000** | 0.082 | 1.085 | 0.942 | 1.251 | 0.257 |
| **Urbanizationa** |  |  |  |  |  |
| **Level 1** |  | 1 |  |  |  |
| **Level 2** | 0.0242 | 1.024 | 0.958 | 1.095 | 0.4787 |
| **Level 3** | -0.0835 | 0.92 | 0.791 | 1.07 | 0.28 |
| **Level 4 (rural area)** | 0.0256 | 1.026 | 0.73 | 1.441 | 0.8824 |
| **Outpatient Visits of Cardiology, in the past one year** |  |  |  |  |  |
| **0 visits** |  | 1 |  |  |  |
| **1**−**5 visits** | -0.097 | 0.908 | 0.829 | 0.993 | 0.0348 |
| **6**−**10 visits** | -0.0539 | 0.947 | 0.817 | 1.099 | 0.4751 |
| **>10 visits** | 0.0167 | 1.017 | 0.856 | 1.209 | 0.8498 |
| **Outpatient Visits of Metabolism &Endocrinology, in the past one year** |  |  |  |  |  |
| **0 visits** |  | 1 |  |  |  |
| **1**−**5 visits** | -0.1408 | 0.869 | 0.771 | 0.979 | 0.0213 |
| **6**−**10 visits** | -0.1619 | 0.851 | 0.686 | 1.054 | 0.1398 |
| **>10 visits** | -0.1672 | 0.846 | 0.628 | 1.139 | 0.2705 |
| **Charlson Comorbidity Index Scoreb** | -0.0643 | 0.938 | 0.913 | 0.963 | <.0001 |
| **Duration of diagnosis of diabetes, month** | -0.0015 | 0.999 | 0.997 | 1 | 0.0122 |
| **Adapted Diabetes Complications Severity Index scorec** | -0.0394 | 0.961 | 0.937 | 0.987 | 0.0028 |
| **Hospitalization for peripheral arterial disease** | -1.6845 | 0.186 | 0.126 | 0.272 | <.0001 |
| **Drugs for diabetes** |  |  |  |  |  |
| **Acarbose inhibits enzymes** | 0.3834 | 1.467 | 1.284 | 1.677 | <.0001 |
| **Sulfonylurea** | 0.2496 | 1.283 | 1.194 | 1.38 | <.0001 |
| **Insulin** | -0.156 | 0.856 | 0.671 | 1.091 | 0.2077 |
| **Metformin** | 0.2865 | 1.332 | 1.239 | 1.432 | <.0001 |
| **Thiazolidinediones** | 0.1073 | 1.113 | 0.959 | 1.292 | 0.1583 |
| **Glinide** | 0.1578 | 1.171 | 0.985 | 1.392 | 0.0741 |
| **Dipeptidyl peptidase-4 inhibitor** | 0.2712 | 1.312 | 0.938 | 1.834 | 0.113 |
| **Anti-hypertensive drug** |  |  |  |  |  |
| **ACE inhibitor or ARB** | 0.0735 | 1.076 | 0.994 | 1.165 | 0.0701 |
| **Alpha-blocker** | -0.1273 | 0.881 | 0.728 | 1.066 | 0.1912 |
| **Beta-blocker** | 0.3213 | 1.379 | 1.269 | 1.499 | <.0001 |
| **Calcium channel blocker** | 0.0519 | 1.053 | 0.975 | 1.138 | 0.1871 |
| **Diuretics** | 0.0877 | 1.092 | 0.989 | 1.205 | 0.0814 |
| **Other anti-hypertensive drug** | 0.4271 | 1.533 | 1.271 | 1.848 | <.0001 |
| **Other concomitant medications** |  |  |  |  |  |
| **Antiplatelet** d | 0.1055 | 1.111 | 1.024 | 1.206 | 0.0115 |
| **Steroid** | -0.1214 | 0.886 | 0.778 | 1.008 | 0.0664 |
| **Nitrate** | -0.0342 | 0.966 | 0.814 | 1.148 | 0.6966 |
| **NSAID** | 0.0705 | 1.073 | 0.996 | 1.156 | 0.0625 |
| **PPI** | -0.533 | 0.587 | 0.452 | 0.762 | <.0001 |
| **SSRI** | -0.2783 | 0.757 | 0.574 | 0.999 | 0.0493 |
| **Comorbidities** |  |  |  |  |  |
| **Coronary artery disease** | 0.2272 | 1.255 | 1.162 | 1.355 | <.0001 |
| **Cerebrovascular disease** | 0.0757 | 1.079 | 0.986 | 1.18 | 0.0988 |
| **Hypertension** | 0.3348 | 1.398 | 1.285 | 1.521 | <.0001 |
| **Heart failure** | 0.0538 | 1.055 | 0.932 | 1.194 | 0.3941 |
| **Peptic ulcer disease** | 0.1189 | 1.126 | 1.046 | 1.213 | 0.0016 |
| **Liver disease** | 0.2403 | 1.272 | 1.185 | 1.365 | <.0001 |
| **Chronic kidney disease** | 0.231 | 1.26 | 1.136 | 1.397 | <.0001 |
| **Atrial fibrillation** | -0.3579 | 0.699 | 0.55 | 0.889 | 0.0035 |
| **Valvular heart disease** | -0.1451 | 0.865 | 0.764 | 0.98 | 0.0224 |
| **Cancer** | 0.0267 | 1.027 | 0.901 | 1.17 | 0.6879 |
| **Physically limiting conditions** | -0.0185 | 0.982 | 0.881 | 1.093 | 0.7366 |
| **Autoimmune disease** | -0.1686 | 0.845 | 0.713 | 1.001 | 0.0508 |
| a Urbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.  b Charlson Comorbidity Index score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the cumulative mortality[.](#_ENREF_9)  cAdapted Diabetes Complications Severity Index is a 13-point scale from 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic, ranging from each complication. Each complication produced a numeric score ranging from 0 to 2 (0 = no abnormality, 1 = some abnormality, 2 = severe abnormality)  d Including aspirin, clopidogrel, ticlopidine and cilostazol.  *Abbreviations:* NT dollars, new Taiwan dollars; NSAID, Non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, Selective serotonin re-uptake inhibitors. | | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Supplemental eTable 3. Baseline Characteristics of Diabetes Patients With Peripheral Arterial Disease Using Statin and Matched Control After Propensity-Score Matched** | | | |
|  | **Propensity score matched** | | |
| **Characteristics** | **Statin user** | **Non-user** | **Standardized difference** a |
| **Patient (no.)** | 11,373 | 11,373 |  |
| **Mean age (SD), year** | 62.3 (11.5) | 62.2 (12.7) | 0.005 |
| **Male** | 2,007 (17.6) | 5,004 (44.0) | 0.001 |
| **Monthly income, NT$** |  |  |  |
| **Dependent** | 3,659 (32.2) | 3,635 (32.0) | 0.005 |
| **<19,100** | 2,135 (18.8) | 2,162 (19.0) | -0.006 |
| **19,100**−**41,999** | 4,921 (43.3) | 4,913 (43.2) | 0.001 |
| **≥42,000** | 658 (5.8) | 663 (5.8) | -0.002 |
| **Urbanizationb** |  |  |  |
| **Level 1** | 4,135 (36.4) | 4,123 (36.3) | 0.002 |
| **Level 2** | 6,540 (57.5) | 6,572 (57.8) | -0.006 |
| **Level 3** | 601 (5.3) | 565 (5.0) | 0.014 |
| **Level 4 (rural area)** | 97 (0.9) | 113 (1.0) | -0.015 |
| **Outpatient Visits of Metabolism &Endocrinology, in the past one year** |  |  |  |
| **0 visits** | 9,545 (83.9) | 9,539 (83.9) | 0.001 |
| **1**−**5 visits** | 1,142 (10.0) | 1,187 (10.4) | -0.013 |
| **6**−**10 visits** | 440 (3.9) | 413 (3.6) | 0.012 |
| **>10 visits** | 246 (2.2) | 234 (2.1) | 0.007 |
| **Outpatient Visits of Cardiology, in the past one year** |  |  |  |
| **0 visits** | 7,456 (65.6) | 7,445 (65.5) | 0.002 |
| **1**−**5 visits** | 2,245 (19.7) | 2,268 (19.9) | -0.005 |
| **6**−**10 visits** | 1,034 (9.1) | 1,005 (8.8) | 0.009 |
| **>10 visits** | 638 (5.6) | 655 (5.8) | -0.006 |
| **Duration of diabetes mellitus, months (IQR)** | 21 (3-58) | 21 (3-56) | 0.013 |
| **Adapted Diabetes Complications Severity Index scorec** | 3.5 (2.2) | 3.5 (2.2) | 0.008 |
| **Anti-hyperglycemic drug** |  |  |  |
| **Insulin** | 295 (2.6) | 299 (2.6) | -0.002 |
| **Acarbose** | 762 (6.7) | 722 (6.3) | 0.014 |
| **Metformin** | 4,700 (41.3) | 4,721 (41.5) | -0.004- |
| **Sulfonylurea** | 4,178 (36.7) | 4,185 (36.8) | -0.001 |
| **Thiazolidinedione** | 902 (7.9) | 845 (7.4) | 0.019 |
| **Glinide** | 480 (4.2) | 464 (4.1) | 0.007 |
| **DPP-4 inhibitor** | 158 (1.4) | 156 (1.4) | 0.002 |
| **Charlson Comorbidity Index Scored** | 4.8 (2.4) | 4.8 (2.5) | 0.000 |
| **Anti-hypertensive drug** |  |  |  |
| **Alpha-blocker** | 403 (3.5) | 430 (3.8) | -0.013 |
| **ACE inhibitor or ARB** | 3,989 (35.1) | 3,984 (35.0) | 0.001 |
| **Beta-blocker** | 2,183 (19.2) | 2,144 (18.9) | 0.009 |
| **Calcium channel blocker** | 3,826 (33.6) | 3,810 (33.5) | 0.003 |
| **Diuretics** | 1,799 (15.8) | 1,789 (15.7) | 0.002 |
| **Other anti-hypertensive drug** | 186 (1.6) | 189 (1.7) | -0.002 |
| **Other concomitant medications** |  |  |  |
| **Antiplatelet agent**e | 3,860 (33.9) | 3,889 (34.2) | -0.005 |
| **Steroid** | 804 (7.1) | 790 (6.9) | 0.005 |
| **Nitrate** | 715 (6.3) | 710 (6.2) | 0.002 |
| **NSAID** | 2,815 (24.8) | 2,787 (24.5) | 0.006 |
| **PPI** | 291 (2.6) | 317 (2.8) | -0.014 |
| **SSRI** | 239 (2.1) | 245 (2.2) | -0.004 |
| **Comorbidities** |  |  |  |
| **Coronary artery disease** | 5,736 (50.4) | 5,748 (50.5) | -0.002 |
| **Cerebrovascular disease** | 3,739 (32.9) | 3,733 (32.8) | 0.001 |
| **Hypertension** | 9,103 (80.0) | 9,103 (80.0) | -0.000 |
| **Heart failure** | 1,662 (14.6) | 1,620 (14.2) | 0.011 |
| **Peptic ulcer disease** | 6,057 (53.3) | 6,098 (53.6) | -0.007 |
| **Liver disease** | 4,686 (41.2) | 4,737 (41.7) | -0.009 |
| **Chronic kidney disease** | 2,166 (19.0) | 2,177 (19.1) | -0.002 |
| **Atrial fibrillation** | 336 (3.0) | 306 (2.7) | 0.016 |
| **Valvular heart disease** | 1,243 (10.9) | 1,314 (11.6) | -0.020 |
| **Cancer** | 1,130 (9.9) | 1,132 (10.0) | -0.001 |
| **Physically limiting conditions** | 1,462 (12.9) | 1,447 (12.7) | 0.004 |
| **Autoimmune disease** | 573 (5.0) | 581 (5.1) | -0.003 |
| **Propensity score** | 0.24 (0.11) | 0.24 (0.11) | 0.000 |
| \* All data were descripted as number (%), except mean age and propensity score.  **a** Imbalance defined as absolute value >0.100  bUrbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.  cAdapted Diabetes Complications Severity Index is a 13-point scale from 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic, ranging from each complication. Each complication produced a numeric score ranging from 0 to 2 (0 = no abnormality, 1 = some abnormality, 2 = severe abnormality).  dCharlson Comorbidity Index score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the cumulative mortality[.](#_ENREF_9)  eIncluding aspirin, clopidogrel, ticlopidine and cilostazol.  *Abbreviations:* SD, standard deviation; NT$, new Taiwan dollars; ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; NSAIDs, Non-steroidal anti-inflammatory drugs; SSRI, Selective serotonin re-uptake inhibitors. | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Supplemental eTable 4. Baseline Characteristics of Diabetes Patients With Peripheral Arterial Disease Using Non-Statin Lipid Lower Agent and Matched Control After Propensity-Score Matched** | | | |
|  | **Propensity score matched** | | |
| **Characteristics** | **Non-Statin Lipid Lowering Agent User** | **Non-user** | **Standardized difference** a |
| **Patient (no.)** | 4,428 | 4,428 |  |
| **Mean age (SD), year** | 57.9 (12.0) | 57.9 (12.8) | -0.003 |
| **Male** | 2,400 (54.2) | 2,347 (53.0) | 0.024 |
| **Monthly income, NT$** |  |  |  |
| **Dependent** | 1,108 (25.0) | 1,063 (24.0) | 0.024 |
| **<19,100** | 860 (19.4) | 866 (19.6) | -0.003 |
| **19,100**−**41,999** | 2,160 (48.8) | 2,205 (49.8) | -0.020 |
| **≥42,000** | 300 (6.8) | 294 (6.6) | 0.005 |
| **Urbanizationb** |  |  |  |
| **Level 1** | 1,565 (35.3) | 1,515 (34.2) | 0.024 |
| **Level 2** | 2,613 (59.0) | 2,666 (60.2) | -0.024 |
| **Level 3** | 212 (4.8) | 204 (4.6) | 0.009 |
| **Level 4 (rural area)** | 38 (0.9) | 43 (1.0) | -0.012 |
| **Outpatient Visits of Metabolism &Endocrinology, in the past one year** |  |  |  |
| **0 visits** | 3,960 (89.4) | 3,973 (89.7) | -0.010 |
| **1**−**5 visits** | 323 (7.3) | 302 (6.8) | 0.019 |
| **6**−**10 visits** | 96 (2.2) | 100 (2.3) | -0.006 |
| **>10 visits** | 49 (1.1) | 53 (1.2) | -0.008 |
| **Outpatient Visits of Cardiology, in the past one year** |  |  |  |
| **0 visits** | 3,338 (75.4) | 3,314 (74.8) | 0.013 |
| **1**−**5 visits** | 684 (15.4) | 713 (16.1) | -0.018 |
| **6**−**10 visits** | 232 (5.2) | 216 (4.9) | 0.016 |
| **>10 visits** | 174 (3.9) | 185 (4.2) | -0.013 |
| **Duration of diabetes mellitus, months (IQR)** | 14 (3-47) | 15 (3-47) | -0.011 |
| **Adapted Diabetes Complications Severity Index scorec** | 2.9 (2.0) | 2.9 (2.0) | 0.016 |
| **Anti-hyperglycemic drug** |  |  |  |
| **Insulin** | 76 (1.7) | 92 (2.1) | -0.026 |
| **Acarbose** | 286 (6.5) | 282 (6.4) | 0.004 |
| **Metformin** | 1,745 (39.4) | 1,766 (39.9) | -0.010 |
| **Sulfonylurea** | 1,592 (36.0) | 1,611 (36.4) | -0.009 |
| **Thiazolidinedione** | 229 (5.2) | 246 (5.6) | -0.017 |
| **Glinide** | 156 (3.5) | 156 (3.5) | 0.000 |
| **DPP-4 inhibitor** | 44 (1.0) | 51 (1.2) | -0.015 |
| **Charlson Comorbidity Index Scored** | 4.4 (2.3) | 4.3 (2.3) | 0.019 |
| **Anti-hypertensive drug** |  |  |  |
| **Alpha-blocker** | 126 (2.8) | 102 (2.3) | 0.034 |
| **ACE inhibitor or ARB** | 1,164 (26.3) | 1,157 (26.1) | 0.004 |
| **Beta-blocker** | 905 (20.4) | 885 (20.0) | 0.011 |
| **Calcium channel blocker** | 1,296 (29.3) | 1,258 (28.4) | 0.019 |
| **Diuretics** | 575 (13.0) | 557 (12.6) | 0.012 |
| **Other anti-hypertensive drug** | 134 (3.0) | 119 (2.7) | 0.020 |
| **Other concomitant medications** |  |  |  |
| **Antiplatelet agent**e | 1,027 (23.2) | 1,006 (22.7) | 0.011 |
| **Steroid** | 277 (6.3) | 264 (6.0) | 0.012 |
| **Nitrate** | 166 (3.7) | 168 (3.8) | -0.002 |
| **NSAID** | 1,081 (24.4) | 1,077 (24.3) | 0.002 |
| **PPI** | 62 (1.4) | 37 (0.8) | 0.054 |
| **SSRI** | 56 (1.3) | 56 (1.3) | 0.000 |
| **Comorbidities** |  |  |  |
| **Coronary artery disease** | 1,911 (43.2) | 1,882 (42.5) | 0.013 |
| **Cerebrovascular disease** | 1,105 (25.0) | 1,110 (25.1) | -0.003 |
| **Hypertension** | 3,329 (75.2) | 3,335 (75.3) | -0.003 |
| **Heart failure** | 468 (10.6) | 451 (10.2) | 0.013 |
| **Peptic ulcer disease** | 2,230 (50.4) | 2,195 (49.6) | 0.016 |
| **Liver disease** | 2,044 (46.2) | 2,023 (45.7) | 0.010 |
| **Chronic kidney disease** | 773 (17.5) | 724 (16.4) | 0.030 |
| **Atrial fibrillation** | 78 (1.8) | 72 (1.6) | 0.010 |
| **Valvular heart disease** | 330 (7.5) | 316 (7.1) | 0.012 |
| **Cancer** | 374 (8.4) | 376 (8.5) | -0.002 |
| **Physically limiting conditions** | 449 (10.1) | 444 (10.0) | 0.004 |
| **Autoimmune disease** | 154 (3.5) | 165 (3.7) | -0.013 |
| **Propensity score** | 0.10 (0.06) | 0.10 (0.06) | 0.000 |
| \* All data were descripted as number (%), except mean age and propensity score.  **a** Imbalance defined as absolute value >0.100  bUrbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.  cAdapted Diabetes Complications Severity Index is a 13-point scale from 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic, ranging from each complication. Each complication produced a numeric score ranging from 0 to 2 (0 = no abnormality, 1 = some abnormality, 2 = severe abnormality).  dCharlson Comorbidity Index score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the cumulative mortality[.](#_ENREF_9)  eIncluding aspirin, clopidogrel, ticlopidine and cilostazol.  *Abbreviations:* SD, standard deviation; NT$, new Taiwan dollars; ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; NSAIDs, Non-steroidal anti-inflammatory drugs; SSRI, Selective serotonin re-uptake inhibitors. | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplemental eTable 5.** **Subgroup Analysis of Risk of Lower Extremity Amputation among Statin User and Matched Non-user.** | | | | |
| **Characteristic** | **Hazard Ratio\***  **(95% CI)** | ***P* Value** | | **Interaction**  ***P* Value** |
| **Gender** |  |  |  | |
| **Male** | 0.718 (0.534-0.967) | 0.029 | | 0.688 |
| **Female** | 0.792 (0.555-1.130) | 0.198 | |  |
| **Age** |  |  |  | |
| **20-65 years** | 0.777 (0.566-1.065) | 0.117 | | 0.718 |
| **>65 years** | 0.721 (0.519-1.001) | 0.051 | |  |
| **Charlson Comorbidity Index score** |  |  |  | |
| **2** | 0.633 (0.362-1.107) | 0.109 | | 0.357 |
| **3** | 0.532 (0.272-1.040) | 0.065 | |  |
| **4** | 1.123 (0.625-2.018) | 0.697 | |  |
| **≧5** | 0.745 (0.549-1.012) | 0.060 | |  |
| **Hypertension** |  |  |  | |
| **Yes** | 0.738 (0.573-0.951) | 0.019 | | 0.777 |
| **No** | 0.803 (0.479-1.348) | 0.406 | |  |
| **Chronic kidney disease** |  |  |  | |
| **Yes** | 0.935 (0.624-1.401) | 0.744 | | 0.206 |
| **No** | 0.676 (0.512-0.892) | 0.006 | |  |
| **Heart failure** |  |  |  | |
| **Yes** | 0.927 (0.580-1.482) | 0.753 | | 0.296 |
| **No** | 0.696 (0.535-0.904) | 0.007 | |  |
| **Coronary artery disease** |  |  |  | |
| **Yes** | 0.758 (0.549-1.045) | 0.091 | | 0.963 |
| **No** | 0.744 (0.539-1.028) | 0.073 | |  |
| **Using antiplatelet agent** |  |  |  | |
| **Yes** | 0.725 (0.518-1.015) | 0.061 | | 0.768 |
| **No** | 0.773 (0.567-1.054) | 0.104 | |  |
| **High potency** |  |  |  | |
| **Yes** | 0.865 (0.362-2.066) | 0.743 | | 0.703 |
| **No** | 0.738 (0.582-0.934) | 0.012 | |  |
| **\*** Non-user cohort: reference group  Abbreviations: CI, confidence interval. | | | | |